PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29207614-6	2017	Second, 10 muM DT repressed the phosphorylation of signal transducer and activator of transcription 3 (STAT3), the protein expression of S-phase kinase associated protein-2 (Skp2), and the mRNA levels of STAT3-related genes, including chemokine (C-C motif) ligand 2 (CCL2).	dihydroisotanshinone I	15-17	C-C motif chemokine ligand 2	Homo sapiens	235-265	
29207614-6	2017	Second, 10 muM DT repressed the phosphorylation of signal transducer and activator of transcription 3 (STAT3), the protein expression of S-phase kinase associated protein-2 (Skp2), and the mRNA levels of STAT3-related genes, including chemokine (C-C motif) ligand 2 (CCL2).	dihydroisotanshinone I	15-17	C-C motif chemokine ligand 2	Homo sapiens	267-271	
29207614-7	2017	In addition, 10 muM DT suppressed the macrophage recruitment ability of lung cancer cells by reducing CCL2 secretion from both macrophages and lung cancer cells.	dihydroisotanshinone I	20-22	C-C motif chemokine ligand 2	Homo sapiens	102-106	
28157698-0	2017	Anti-cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway.	dihydroisotanshinone I	34-56	C-C motif chemokine ligand 2	Homo sapiens	166-170	
28157698-5	2017	Mechanistically, DT both diminished the ability of prostate cancer cells to recruit macrophages and reduced the secretion of chemokine (C-C motif) ligand 2 (CCL2) from both macrophages and prostate cancer cells in a dose-dependent manner.	dihydroisotanshinone I	17-19	C-C motif chemokine ligand 2	Homo sapiens	125-155	
28157698-5	2017	Mechanistically, DT both diminished the ability of prostate cancer cells to recruit macrophages and reduced the secretion of chemokine (C-C motif) ligand 2 (CCL2) from both macrophages and prostate cancer cells in a dose-dependent manner.	dihydroisotanshinone I	17-19	C-C motif chemokine ligand 2	Homo sapiens	157-161	
28157698-9	2017	Furthermore, DT can inhibit the migration of prostate cancer cells by interrupting the crosstalk between prostate cancer cells and macrophages via the inhibition of the CCL2/STAT3 axis.	dihydroisotanshinone I	13-15	C-C motif chemokine ligand 2	Homo sapiens	169-173	
29386061-0	2018	Dihydroisotanshinone I combined with radiation inhibits the migration ability of prostate cancer cells through DNA damage and CCL2 pathway.	dihydroisotanshinone I	0-22	C-C motif chemokine ligand 2	Homo sapiens	126-130	
29386061-8	2018	Mechanistically, DT and the combination treatment reduced the secretion of chemokine (C-C Motif) Ligand 2 (CCL2) from prostate cancer cells.	dihydroisotanshinone I	17-19	C-C motif chemokine ligand 2	Homo sapiens	75-105	
29386061-8	2018	Mechanistically, DT and the combination treatment reduced the secretion of chemokine (C-C Motif) Ligand 2 (CCL2) from prostate cancer cells.	dihydroisotanshinone I	17-19	C-C motif chemokine ligand 2	Homo sapiens	107-111	
29386061-10	2018	CONCLUSIONS: DT displays radiosensitization and antimigration effects in prostate cancer cells by inducing DNA damage and inhibiting CCL2 secretion.	dihydroisotanshinone I	13-15	C-C motif chemokine ligand 2	Homo sapiens	133-137	
28807849-13	2017	In addition, DT also blocked the colon cancer cells recruitment ability of macrophage by decreasing CCL2 secretion in macrophages.	dihydroisotanshinone I	13-15	C-C motif chemokine ligand 2	Homo sapiens	100-104